Deep Tech Startups

Fundamental.ai develops large language models built from first principles, with each component designed around explicit mathematical understanding rather than opaque emergent behavior. The company positions its approach as an alternative to conventional LLM training, aiming for more interpretable and predictable AI.

1 investor

Furientis develops low-cost interceptor munitions and precision guidance systems, including multimodal seekers and solid rocket motors engineered for high-volume manufacturing. It designs and flight-tests defensive missile hardware aimed at the defense and aerospace sector.

1 investor

Fuse Vectors develops AAV manufacturing platforms for biotech researchers and developers, enabling efficient production from early discovery screening through preclinical validation to clinical-grade manufacturing.

1 investor

Fusion Engineering develops flight controller hardware and software for multirotor drones, focused on safety and reliability to enable certified drone flights over urban areas and in offshore conditions. It targets drone applications seeking to meet EU regulations, serving the broader drone industry.

1 investor

Fusion Bionic, a Fraunhofer IWS spin-off, develops laser-based surface functionalization technology using Direct Laser Interference Patterning (DLIP) to create bioinspired textures with effects such as self-cleaning, anti-icing, and antibacterial properties. It supplies modular laser interference systems to industries including automotive, aerospace, medical technology, photovoltaics, and consumer electronics.

1 investor

Fusion Antibodies optimizes antibody development for research and therapeutic applications. The company serves pharmaceutical and biotech customers seeking to enhance antibody performance.

1 investor

Future Ventures is an early-stage venture capital firm that makes seed and early-stage investments in mission-driven founders building frontier and deep technology across industries. Its portfolio spans areas such as space, nuclear fusion, alternative proteins, quantum computing, and AI applications.

1 investor

FuturedMe develops small-molecule drug candidates using CANDDY, a protein-degradation platform licensed from Tokyo University of Science that induces direct proteasomal degradation of disease-related proteins instead of inhibiting them. The company aims to create therapies for patients with previously undruggable targets and no existing treatment options.

1 investor

Fuzionaire develops chemistry technology based on Earth-abundant alkali metal catalysts and reagents (its ionic alkali metal / IAM platform) for applications in medicine, energy, and materials. The platform originated from discoveries at Caltech, UCLA, and other institutions and targets molecular-level innovation across pharmaceuticals, clean energy, and advanced materials.

1 investor

Fuzionaire Theranostics develops radiopharmaceuticals for oncology using its HetSiFA silicon (SiFA) chemistry platform, creating chemically matched fluorine-18 PET diagnostic and radioligand therapy pairs. Its lead program, FTX-426, targets GRPR-expressing solid tumors such as prostate and breast cancer.

1 investor

FW Robotics builds custom underwater and deep-environment robotic platforms tailored to each client's requirements, for both industrial and research applications. The systems are designed to be adaptable and maintainable as customer needs change.

1 investor

FYLA develops and manufactures ultrafast fiber lasers and non-invasive quality inspection systems for spectroscopy, microscopy, biophotonics, and semiconductor production. The company serves research institutions, industrial manufacturers, and quality control teams.

1 investor

Fynd Reality develops immersive training platforms using virtual and augmented reality technologies for professional development across industries. The company serves organizations seeking to deliver immersive educational experiences to their workforce.

1 investor

Fziomed develops proprietary dual-polymer gel technology for use across multiple surgical applications. The company focuses on providing innovative solutions for surgical procedures.

1 investor

FZU is the Institute of Physics of the Czech Academy of Sciences, a public research institution conducting work in areas such as condensed matter physics, particle physics, cosmic radiation, and astronomical observation. It participates in international projects including CERN experiments and the Vera C. Rubin Observatory.

1 investor

G2Q Computing develops hybrid quantum-classical software that runs on High-Performance Computing systems and quantum computers to accelerate optimization and machine learning tasks. Its solutions target industries such as financial services, Earth observation/satellite data, and multiphysics engineering simulation.

1 investor

G2V builds tunable LED-based solar simulators used by researchers and engineers working in solar power, aerospace, and materials science to reproduce accurate sunlight for testing. Its products replace gas-discharge-lamp systems with LED technology aimed at precise, repeatable solar simulation.

1 investor

Gadfin develops hydrogen-powered drones with payloads of 3 to 150 kg designed for time-critical deliveries and maintenance missions in remote areas. The company serves medical facilities, logistics providers, and infrastructure operators with autonomous delivery systems that combine extended flight range, low acoustic signature, and emission-free operation.

1 investor

GAIA Refinery develops a bio-electrochemical direct air capture platform that uses biogenic ethanol rather than heat or high-voltage grid power to capture and concentrate atmospheric CO₂ at ambient temperature for permanent underground storage. It targets project partners who provide sites, geological storage, or demand for removal-grade carbon credits, positioning its modular units for deployment at sequestration sites across North America and beyond.

1 investor

Galaxea AI provides a platform for developing embodied AI systems, offering data collection, quality assurance, model post-training, and deployment tools for robotics developers. The platform integrates open-source embodied AI models and proprietary models (G0, G0.5 series) with one-click fine-tuning capabilities.

1 investor

Galen builds causal, computational models of living cells ("virtual cells") that aim to predict how a cell changes under a given intervention before experiments are run. Its initial focus is durability and exhaustion in engineered T cell therapies, serving scientists and drug developers working on cell therapies.

1 investor

Galenica distributes Leica confocal microscopes for biomedical research, enabling high-precision imaging of subcellular structures and dynamic cellular processes at nanoscopic resolution.

1 investor

Galventa develops delivery technologies for food supplements and over-the-counter products designed to optimize dosage timing and bioavailability. The company focuses on improving the efficacy of nutraceutical formulations through galenic innovation.

1 investor

GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.

1 investor